Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

Collaboration leverages Variant Bio’s cutting-edge genomic discovery platform and Evotec’s integrated end-to-end R&D platform and disease area expertise. Photo credit, from the Variant Bio lab in Seattle: Sarah LeBaron von Baeyer

Today I’m excited to announce a strategic, risk-sharing partnership between Variant Bio and Evotec. The partnership will leverage Variant Bio’s cutting-edge genomic discovery capabilities and VB-Inference platform as well as Evotec’s extensive expertise in antifibrotic drug discovery. In the months to come, we will work with Evotec to identify best-in-class small molecules targeting a key fibrotic pathway with strong genetic support identified by Variant Bio. This will allow us to progress our fibrosis program toward the selection of one or more clinical development candidates. We are thrilled to combine our areas of expertise to develop a therapeutic that we believe could have a significant impact on patient health worldwide.

Details of the collaboration can be found in a press release here.